Tava

View All

Personalized Medicine
Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter

Allergan can finally sell its losing stake in Teva. Will it? Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair’s $40 billion-plus generics deal, currently stands as Teva’s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked do...

Find More